Comparing two blood thinners for staph bloodstream infections
Treatments studied
Part of Heart & circulation, Infections clinical trials.
This study compares two types of blood thinners (dabigatran vs. a common Xa inhibitor like apixaban) in people with a staph infection in their blood. The goal is to see which is safer and works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking or about to start a blood thinner like apixaban, edoxaban, or rivaroxaban for a reason such as atrial fibrillation (irregular heartbeat), a blood clot in your leg or lung, or after hip or knee replacement surgery, with at least 30 days of treatment left.
- You have a staph infection in your bloodstream.
- You have not used dabigatran in the past month and are not allergic to it.
- You are not taking certain other medications (like amiodarone, ketoconazole, rifampin, verapamil, clopidogrel, prasugrel, or ticagrelor).
- Your kidney function is adequate (eGFR at least 30 mL/min). If it is temporarily low, you may be able to join if it improves within 5 days.
- You are not pregnant, do not have active bleeding, do not need major heart, brain, or spine surgery in the next 3 days, and do not have a mechanical heart valve, a clot in the heart's left ventricle, or a condition called antiphospholipid antibody syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two blood-thinning medicines, clopidogrel and aspirin, to see which better prevents heart attacks and strokes in people who have had a staph infection in their blood. If you already take aspirin for heart or blood vessel problems, this study may help find the safest way to protect your heart.
This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This study tests two different blood-thinning medicines to see which is better at preventing another stroke in people who recently had a stroke with no clear cause. The goal is to find a treatment that works well and is safe for you.
This study compares two blood thinners, edoxaban and apixaban, to see how they affect new brain lesions seen on MRI in people who have had a stroke and also have atrial fibrillation. It aims to find which might be safer for preventing future brain damage.
This study tests whether a common blood thinner (apixaban) alone is as safe and effective as combining it with another drug (clopidogrel) to prevent future strokes in people who have both atrial fibrillation and narrowing in the arteries leading to the brain. It aims to find the best way to reduce stroke risk while minimizing bleeding.
Hear when a new Staphylococcus Aureus Endocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.